

Meet Our Editorial Board Member

Pradeep J. Nathan

Heptares Therapeutics Ltd and University of Cambridge
BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX, UK

Prof. Pradeep Nathan is the Vice President of CNS Clinical Development and Experimental Medicine at Heptares Therapeutics Ltd. He is also a Professor of Neuroscience at Monash University and a Professor of Pharmacology at Swinburne University.

Pradeep is trained as a pharmacologist and cognitive neuroscientist with research interests in the neuropharmacology and neural substrates of cognition and emotion and psychiatric and neurological endophenotypes. His expertise lies in the use of cognitive, functional and molecular neuroimaging techniques (i.e. fMRI, Electrophysiology, PET) to understand where and how neuropharmacological agents modulate cognitive and emotional processes and associated neural networks. Through his role in Industry, he is also interested in the application of these approaches to CNS drug discovery through development of functional biomarkers which might aid in the development of more refined and targeted treatment approaches for cognitive and emotional dysfunction in psychiatric and neurological disorders.

Pradeep has published over 200 peer reviewed papers, cited over 10,000 times and has an H-index of 50.



Pradeep J. Nathan

SELECTED PUBLICATIONS

- [1] Labuschagne, I.; Phan, K.L.; Wood, A.; Angstadt, M.; Chua, P.; Heinrichs, M.; Stout, J.C.; Nathan, P.J. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. *Neuropsychopharmacology*, **2010**, 35(12), 2403-2413.
- [2] Lu, B.; Nagappan, G.; Guan, X.; Nathan, P.J.; Wren, P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. *Nat. Rev. Neurosci.*, **2013**, 14(6), 401-416.
- [3] Lim, Y.Y.; Villemagne, V.L.; Laws, S.M.; Ames, D.; Pietrzak, R.H.; Ellis, K.A.; Harrington, K.D.; Bourgeat, P.; Salvado, O.; Darby, D.; Snyder, P.J.; Bush, A.I.; Martins, R.N.; Masters, C.L.; Rowe, C.C.; Nathan, P.J.; Maruff, P. Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. *Neurobiol. Aging*, **2013**, 34(11), 2457-2464.
- [4] Nathan, P.J.; Watson, J.; Lund, J.; Davies, C.H.; Peters, G.; Dodds, C.M.; Swirski, B.; Lawrence, P.; Bentley, G.D.; O'Neill, B.V.; Robertson, J.; Watson, S.; Jones, G.A.; Maruff, P.; Croft, R.J.; Laruelle, M.; Bullmore, E.T. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. *Int. J. Neuropsychopharmacol.*, **2013**, 6(4), 721-731.